Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis

BACKGROUND: Lung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival rate of lower than 20% among patients with advanced lung cancer. This study aims to construct a risk model to guide immunotherapy in LUAD patients effectively. MATERIALS AND METHODS: LUAD Bulk RNA-...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Jianfeng, Jiang, Jinni, Zhao, Guofang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424935/
https://www.ncbi.nlm.nih.gov/pubmed/37583701
http://dx.doi.org/10.3389/fimmu.2023.1177847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424935/
https://www.ncbi.nlm.nih.gov/pubmed/37583701
http://dx.doi.org/10.3389/fimmu.2023.1177847

Ejemplares similares